Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues.
Data concerning the effects of GnRHa on weight gain are scarce.


OBJECTIVE
To assess the variation of the body mass index (BMI) in girls during GnRHa treatment for idiopathic central precocious puberty (CPP).


METHODS
Semestral anthropometric data from 176 girls treated with goserelin or leuprorelin were analyzed.


RESULTS
BMI z-score increased from 1.5 +/- 0.1 SD before treatment (n = 176) to 1.7 +/- 0.2 SD after 24 months (n = 61, p = 0.008). In girls with normal weight before treatment, this variation was greater (n = 112, 0.2 +/- 0.1 SD, p = 0.01) than in those who were overweight (n = 63, -0.9 +/- 0.2 SD, p = 0.7). In the goserelin group the weight change adjusted for bone age was greater (n = 28, 0.4 +/- 0.1 SD) than in the leuprorelin group (n = 5, 0.04 +/- 0.1 SD, p = 0.05).


CONCLUSIONS
A slight increase in BMI was noted, mainly in girls with normal weight before treatment. The influence of different GnRHa on weight must be further investigated.
Aguiar
A L
AL
Department of Pediatrics, Federal University of Bahia School of Medicine, Brazil.
Couto-Silva
A C
AC
Vicente
E J
EJ
Freitas
I C
IC
Cruz
T
T
Adan
L
L
D001827:Body Height / Q000187:drug effects / Q000502:physiology; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects / Q000502:physiology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D017273:Goserelin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016729:Leuprolide / Q000494:pharmacology / Q000627:therapeutic use*; D008137:Longitudinal Studies; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies
D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide